PARIS, April 7, 2021 /PRNewswire/ -- In an open
letter, Sanofi Chief Executive Officer Paul
Hudson today outlined several key projects that the company
will implement to increase the impact of its Corporate Social
Responsibility (CSR) strategy. Embedded in Sanofi's long-term
strategy, the company's commitment is based on four essential
pillars in which Sanofi is uniquely positioned to make a
difference: access to medicines, support for vulnerable
communities, preservation of the environment, and inclusion and
diversity of its employees.
"The pandemic has forced us to
question nearly every aspect of our lives: how we live and work,
and how we connect with our communities and the planet. Yet as
challenging as 2020 was, it also brought us –Sanofi and the
pharmaceutical industry– closer to our purpose than at any other
time in living memory," said Hudson. "This unique context
led us to elevate our ambition for our Corporate Social
Responsibility strategy and embed it even more into our mission to
transform lives and our vision for a better future."
Sanofi Global Health, pillar of access to essential
medicines
A cornerstone of Sanofi's CSR strategy, Sanofi
Global Health is a newly formed nonprofit unit within the
company. Leveraging the company's diverse and large portfolio of
medicines and global footprint, Sanofi Global Health is dedicated
to increasing access to medicines considered essential by the World
Health Organization (WHO) for patients in 40 lower income
countries. Thirty of Sanofi's medicines will be provided
across a wide range of therapeutic areas, including cardiovascular
disease, diabetes, tuberculosis, malaria, and cancer. Sanofi
Global Health will also fund the training of healthcare
professionals or the set up and development of sustainable care
systems for those who suffer from chronic diseases and require
complex care.
Sanofi Global Health is the first global initiative to
provide access to such a broad portfolio of medicines, in so many
countries and across several therapeutic areas, while funding local
support programs.
Additionally, Sanofi is committed to helping 1,000 patients
living with rare diseases who have no access to treatments and will
donate 100,000 vials of medicine for their treatments each
year. This continues Sanofi's 30-year commitment to patients
suffering from rare diseases, such as Fabry, Gaucher or Pompe
diseases, for which access to treatment is often limited.
Leveraging R&D efforts to address crucial treatment
gaps
Sanofi continues to support vulnerable communities and
commits to developing innovative medicines for pediatric
cancer, with the ultimate ambition of eliminating cancer
deaths in children. In low- to middle-income countries, a child
is four times more likely to die of pediatric cancers than children
living in high-income countries.
Sanofi also continues its efforts to fight polio and sleeping
sickness, two of its historical programs that address global
health issues. In December 2020,
Sanofi announced it had renewed its five-year partnership with WHO
to fight neglected tropical diseases that affect approximately one
billion people. In this context, Sanofi, the only pharmaceutical
company that continues to develop and supply treatments for African
trypanosomiasis or sleeping sickness, and has committed with the
WHO to eliminate this neglected tropical disease in humans by 2030.
For 40 years, Sanofi has supplied billions of polio vaccine doses,
including hundreds of millions of donated doses to support the
global polio eradication effort.
Zero plastic packaging for vaccines and ecodesign of
products
For several years, Sanofi has been implementing a
global environmental protection program, Planet Mobilization.
Today, the company is amplifying its actions to further improve the
environmental footprint of its products and activities.
To reduce its greenhouse gas emissions by 55% by 2030 and
contribute to better resource conservation, Sanofi plans to
remove all pre-formed plastic packaging (blister packs) for its
vaccines by 2027. The company is also committed to
ecodesigning all its new products by 2025. In terms of
energy management, all Sanofi sites will use 100% renewable
electricity and the company has set a target of a
carbon-neutral car fleet, both by 2030.
Pushing to build more diverse and inclusive
workforce
As a global company, Sanofi is committed to
ensuring that its leaders reflect the communities and patients it
serves. The company is committed to building an organization where
all employees have equal opportunities to reach positions of
responsibility within the company. Sanofi will continue to build a
workforce that is fully reflective of the communities employees
live in and the patients the company serves. This element of the
social impact strategy will be integrated into the career
development of Sanofi leaders worldwide, ensuring a mindset that
fosters diversity and inclusion throughout the company.
"Throughout this pandemic,
public authorities, scientists, and industry have worked closely
together to discover and produce vaccines at a pace that has defied
historical precedent. We now have to apply this same sense of
urgency to other pressing threats, such as climate change, and
issues that the pandemic has sharply put into focus, including
widening racial and healthcare inequalities. Let's always remember
that crises do not just neatly follow one after the other, they
stack up. At Sanofi, we know we can do more," said Hudson.
About Sanofi
Sanofi is dedicated to supporting people
through their health challenges. We are a global biopharmaceutical
company focused on human health. We prevent illness with vaccines,
provide innovative treatments to fight pain and ease suffering. We
stand by the few who suffer from rare diseases and the millions
with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Media Relations
Contact
|
Investor Relations
Contacts Paris
|
Ashleigh
Koss
|
Eva
Schaefer-Jansen
|
Tel: +1 (908)
981-8745
|
Arnaud
Delepine
|
Ashleigh.Koss@sanofi.com
|
|
|
Investor Relations
Contacts North America
|
Sandrine
Guendoul
|
Felix
Lauscher
|
Tel.: +33 (0) 6 25 09
14 25
|
Fara
Berkowitz
|
Sandrine.Guendoul@sanofi.com
|
Suzanne
Greco
|
|
|
|
IR main
line:
|
|
Tel.: +33 (0)1 53 77
45 45
|
|
investor.relations@sanofi.com
|
|
|
|
https://www.sanofi.com/en/investors/contact
|
|
|
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
View original
content:http://www.prnewswire.com/news-releases/sanofi-expands-its-social-commitments-creates-nonprofit-unit-to-provide-poorest-countries-with-access-to-essential-medicines-301263934.html
SOURCE Sanofi